SIHUAN PHARMACEUTICAL (SHPHF)

Thursday

9:12 AM

Thesis: The recent partnerships and product launches have improved investor sentiment, indicating a potential turnaround in growth prospects.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$2.6B	$3.6B	$4.4B
Rev. Growth	+34.2%	+42.6%	+21.8%
EPS	$0.02	$0.07	$0.11
EPS Growth	+181%	+296%	+48.3%
P/E (fwd)	6.3×	1.6×	1.1×

★ Analysts see FY2026 revenue reaching $3.6B — +42.6% growth in a single year.

Why Revenue Could Explode

1Sihuan's recent launch of a new cardiovascular drug is projected to capture 15% of the market share within the first year, significantly boosting revenue.
2The company has secured a partnership with a major international pharmaceutical firm to co-develop a new CNS drug, expected to enhance R&D capabilities.
3Recent regulatory changes in China may streamline the drug approval process, potentially accelerating Sihuan's product launches.
4Growing demand for cardiovascular and CNS medications
5Increased focus on R&D in the Chinese pharmaceutical sector
6Approval of new drug formulations by the National Medical Products Administration (NMPA)
7Changes in healthcare regulations impacting pharmaceutical pricing
8Market share gains in key therapeutic areas

FY2025 Snapshot

Revenue: $2.6B
Rev. Growth: +34.2%
Gross Margin: 68.8%
Op. Margin: 15.0%
Net Margin: 6.9%
Net Income: $175M
NI Growth: +181%
EPS: $0.02
1Y Return: +23.0%

SHPHF Chart

My Notes

"Management emphasized, 'Our new product pipeline is robust, and we are positioned to capture significant market share in the coming quarters.'"
Moat: Sihuan's established brand and distribution network provide a moderate level of competitive advantage…
growth - Investors may be drawn to Sihuan for its high revenue and net income growth rates, indicating strong demand for its products.
Interest rates can affect Sihuan's cost of capital for R&D and expansion projects, as well as consumer spending on healthcare products…
Watch on earnings: NMPA drug approval rates, Market share in cardiovascular and CNS segments, R&D expenditure as a percentage of revenue.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $3.6B to $4.4B as sihuan's recent launch of a new cardiovascular drug is projected to capture 15% of the market share within the first.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance